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ABSTRACT
A Streptozotocin-Induced Model of Alzheimer’s Disease in
Mice with Wild-Type Human Tau
Carolyn C. Rudy
Alzheimer’s disease (AD) accounts for 60 to 80% of all dementias, affects over 5 million
Americans, and incurs annual healthcare costs of over $200 billion (Alzheimer’s Association,
2012). Hyperphosphorylation of tau, the main component of neurofibrillary tangles observed in
AD, leads to deficits in cell structure and function. Because recent data suggest impairments in
cerebral glucose utilization and energy metabolism play a prominent role in the pathogenesis of
AD, we sought to create a mouse model that emulates the metabolic changes using
intracerebroventricular infusions of streptozotocin (ICV-STZ) in transgenic mice expressing
human tau. The Barnes maze, a test of spatial learning and memory, and a panel of antibodies
directed at biochemical changes in tau associated with AD were used to assess memory deficits
and tau pathology, respectively. The behavioral and biochemical findings of the current study
provide inconsistent support for the use of an ICV-STZ model in mice expressing human tau,
and future studies should employ a battery of behavioral assays to determine if subtle memory
deficits occur.
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A Streptozotocin-Induced Model of Alzheimer’s Disease in
Mice with Wild-Type Human Tau
Tauopathies are a group of neurodegenerative disorders involving the tau protein
(Clavaguera et al., 2009). Alzheimer’s disease (AD), the most common tauopathy, accounts for
60 to 80% of all dementias and affects over 5 million Americans (Alzheimer’s Association,
2012). As the American public ages, the societal and economic costs are becoming increasingly
burdensome: unpaid caregivers of AD patients worked over 17.4 billion hours in 2011, and ADrelated health care costs are expected to exceed $200 billion (Alzheimer’s Association, 2012). In
addition to memory loss, other early symptoms of AD include difficulties with problem solving,
regulating one’s emotions, and completing familiar tasks (Alzheimer’s Association, 2012). The
disease progresses over the course of about 4 to 8 years during which cognitive functioning
declines steadily until death (Alzheimer’s Association, 2012). Pharmaceutical treatment of AD,
which cannot halt or slow the progression of cognitive decline (Piau, Nourhashémi, Hein,
Caillaud, & Vellas, 2011), is currently limited to two classes of drugs: uncompetitive N-methylD-aspartate (NMDA) receptor antagonists and reversible acetylcholinesterase inhibitors.
Tau, a microtubule-associated protein, is the main component of neurofibrillary tangles
(NFTs) observed in AD and other neurodegenerative tauopathies (see Kolarova, García-Sierra,
Bartos, Ricny, & Ripova, 2012 for review). NFTs are primarily composed of
hyperphosphorylated tau bound in paired helical filaments (Hong & Lee, 1997; Tokutake et al.,
2012). In AD, NFTs form when tau aggregates in the somatodendritic part of the neuron
(Hébert, Sergeant, & Buée, 2012), eventually resulting in neuronal death. Plaques are a distinct
hallmark of AD and are not found in any other tauopathies. Plaques are composed primarily of
beta-amyloid (Aβ), a 39 to 42 amino acid fragment derived from proteolytic processing of the
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amyloid precursor protein (APP) (Haass et al., 1993; Ittner et al., 2010; Tokutake et al., 2012).
Neuronal death, the third hallmark of AD, is most pronounced in areas of the brain related to
executive functioning and memory, such as the frontal cortex (Lemmens et al., 2011; Sabuncu et
al., 2011) and hippocampus (Sabuncu et al., 2011).
Tau Plays a Significant Role in AD Etiology
Increased production or decreased clearance of Aβ is believed to be the precipitating
event in AD pathogenesis, a theory referred to as the amyloid cascade hypothesis (Hardy &
Higgins, 1992). However, several lines of evidence suggest that, although Aβ pathology may
occur before tau pathology, it does not fully explain the cognitive decline observed in AD. For
example, NFT density is more closely correlated with disease severity than Aβ plaques (Berg et
al., 1998; Kolarova et al., 2012). Aβ plaques are frequently observed in older individuals with
no cognitive dysfunctions; however, it is unusual to find tangles without the presence of AD or
another related tauopathy (Piau et al., 2011). Furthermore, tau pathology alone is capable of
causing the neurodegeneration witnessed in sporadic and familial tauopathies (Sorrentino &
Bonavita, 2007). Further weakening support against the amyloid cascade hypothesis comes from
clinical trials using drugs that lower Aβ levels. Despite successfully lowering Aβ levels, the
drugs do not decrease neuronal death or significantly improve cognitive functioning (Gervais et
al., 2007; Gilman et al., 2005; Klafki, Staufenbiel, Kornhuber, & Wiltfang, 2006; Siemers, Dean,
Demattos, & May, 2006). For these reasons, the current proposal focuses on the role of tau in
AD pathology.
Tau is a microtubule-associated protein responsible for microtubule nucleation and
stabilization in neurons (Eckermann et al., 2007). In the human brain, there are a total of six
isoforms of tau ranging from 352 to 441 amino acids long, with molecular weights between 45
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and 65 kDa (Buée, Bussière, Buée-Scherrer, Delacourte, & Hof, 2000). The different isoforms
are created by alternative splicing of exons 2, 3, and 10 of the tau gene (Luk et al., 2012). Exon
10 is particularly important in tauopathies. Inclusion of exon 10 results in the expression of four
microtubule-binding repeat domains (4R), whereas the exclusion of exon 10 leads to only three
microtubule-binding repeat domains (3R) (Kolarova et al., 2012). Tauopathies often shift from
an approximately 1:1 ratio of 3R to 4R in young, non-demented human brains to an excess of 4R
tau in disease states, which is significant given the increased likelihood of 4R tau to dissociate
from microtubules and aggregate (Adams, DeTure, McBride, Dickson, & Petrucelli, 2010).
As a phosphoprotein, there are over 80 serine and threonine sites on tau that can be
phosphorylated (Billingsley & Kincaid, 1997; Kolarova et al., 2012). The abnormal
phosphorylation of tau is a fundamental neuropathological event in AD (Kolarova et al., 2012). It
is believed to be one of the earliest changes in the brain, with tau becoming more phosphorylated
as the disease progresses (Crespo-Biel, Theunis, & Van Leuven, 2012). The mechanisms by
which tau becomes hyperphosphorylated are not fully understood, though a few have been
identified. Mechanisms that lead to exacerbated tau phosphorylation often involve increased
kinase activity, or decreased phosphatase activity, leading to a decrease in the removal of
phosphate groups from tau (see Iqbal & Grundke-Iqbal, 2008 for review). Some of the kinases
implicated include glycogen synthase kinase 3 beta (GSK3β) (Plattner, Angelo, & Giese, 2006),
cyclin-dependent kinase 5 (Cdk5) (Ahlijanian et al., 2000; Plattner et al., 2006), and calciumand calmodulin-dependent protein kinase-II (CaMKII; Bennecib, Gong, Grundke-Iqbal, & Iqbal,
2001; Singh, Zaidi, Grundke-Iqbal, & Iqbal, 1996). Both GSK3β and Cdk5 are proline-directed
serine/threonine kinases responsible for phosphorylating tau at the sites most implicated in AD
(Plattner et al., 2006). Tau is also phosphorylated at two particular sites by CaMKII, which does
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not belong to the same category of kinases as GSK3β and Cdk5 (Bennecib et al., 2001; Singh et
al., 1996). CaMKII does not phosphorylate tau at nearly as many sites as GSK3β and Cdk5 but
contributes to further hyperphosphorylation (Cho & Johnson, 2003). Similarly, down-regulation
of phosphoseryl/phosphothreonyl protein phosphatase-2A (PP2A), which dephosphorylates tau
at several sites, also contributes to phosphorylation of tau (Gong et al., 2000; Liu, GrundkeIqbal, Iqbal, & Gong, 2005; Wang, Grundke-Iqbal, & Iqbal, 2007). PP2A activity, which is
reduced in AD, further exacerbates the phosphorylation of tau caused by other proline-directed
serine/threonine kinases (Liu & Wang, 2009; Qian et al., 2010). Why the activity of kinases and
phosphatases changes in AD is unclear, but research suggests metabolic abnormalities may play
a role. Early stages of AD are accompanied by metabolic abnormalities, such as a decrease in
insulin levels in the brain (Frӧlich, Blum-Degen, Riederer, & Hoyer, 1999) and a drop in
cerebral glucose utilization (Hoyer & Nitsch, 1989), resulting in alterations of these kinases in
ways that promote tau phosphorylation (de la Monte, 2012). PP2A is also implicated in
negatively regulating the insulin signaling pathway (Mandavia & Sowers, 2012; Ugi et al.,
2004).
Tau hyperphosphorylation can lead to various deficits in cell structure and function. The
hyperphosphorylation of tau prevents proper binding of microtubules, leading to decreased cell
stability (Mongradón-Rodríguez et al., 2008) and axonal transport (Mandelkow, Stamer, Vogel,
Thies, & Mandelkow, 2003). In addition, tau hyperphosphorylation, and the subsequent
unbinding of tau from microtubules, causes tau to mislocalize into the somatodendritic
compartment (Gӧtz, Chen, Barmettler, & Nitsch, 2000) and dendritic spines (Hoover et al.,
2010). In vitro studies suggest that mislocalization of tau to dendritic spines, which is dependent
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upon tau hyperphosphorylation, causes alterations in glutamatergic receptor trafficking, leading
to long-term potentiation (LTP) deficits (Hoover et al., 2010) and presumably memory deficits.
Although tau mutations have been linked to the pathogenesis of some tauopathies,
including frontotemporal dementia (Goedert, Crowther, & Spillantini, 1998), Pick’s disease
(Pickering-Brown et al., 2000), and progressive supranuclear palsy (Ezquerra et al., 1999), there
are no reported tau mutations in AD. To model tau pathology in AD, mutations linked to other
tauopathies are often expressed in mice, and in some cases, the expression is restricted to brain
regions involved in AD through the use of specific promoter systems (i.e., a region of DNA that
initiates transcription of a particular gene). For example, the rTg(TauP301L)4510 mouse (herein
called TauP301L) expresses the proline-to-leucine mutation at the 301st amino acid (P301L) in
human tau associated with frontotemporal dementia and Parkinsonism linked to chromosome 17
(FTDP-17) (Ramsden et al., 2005). To create a more AD-like model, P301L human tau
expression is driven by a forebrain-specific CaMKII promoter system, resulting in high levels of
human tau expression in brain regions related to AD, including the hippocampus and neocortex
(Ramsden et al., 2005). TauP301L mice exhibit age-dependent tau hyperphosphorylation, NFTs,
neuron loss, and memory impairment (Ramsden et al., 2005). Although this model is incredibly
useful and the phenotype closely parallels the tau-related changes observed in AD, identifying
and characterizing the etiology of AD using such a model is not possible given that this tau
mutation does not occur in AD.
To Be Resolved
Here, it was proposed to create a mouse model that closely mimics the precipitating
events believed to underlie AD-related changes and to examine the resulting changes in tau
pathology and memory. Recent data have suggested that impairments in cerebral glucose
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utilization and energy metabolism play an important role in the pathogenesis of AD. The early
stages of cognitive impairment in AD are accompanied, or even preceded, by decrements in
glucose utilization and energy metabolism (de la Monte, 2012; Hoyer, 2004). Furthermore,
insulin injections can improve cognitive functioning in individuals with AD (Craft et al., 1999;
Watson & Craft, 2004). To model the metabolic changes that take place in AD,
intracerebroventricular (ICV) infusions of streptozotocin (STZ) were used. ICV-STZ produces
insulin-resistance in the brain, as well as a myriad of molecular and pathological features that
mimic AD, including tau hyperphosphorylation (Grünblatt, Salkovic-Petrisic, Osmanovic,
Riederer, & Hoyer, 2007). To date, however, effects of ICV-STZ on tau pathology have only
been examined in rodents that have rodent, not human, tau. To determine effects of ICV-STZ on
human tau, the rTg(TauWT)21221 mouse model (herein called TauWT), that expresses wildtype human four-repeat (4R) tau, was used. The TauWT mouse model does not exhibit memory
deficits nor tau pathology (Hoover et al., 2010) but allowed us to foster a determination of effects
of ICV-STZ on 4R human tau – a version of tau that is more prone to AD-related changes
(Barghorn & Mandelkow, 2002) but does not lead to tau pathology on its own (Hoover et al.,
2010). In a healthy brain, there is typically a 1:1 ratio of 3R to 4R tau, but in tauopathies,
including AD, there is a shift to an excess of 4R (Liu & Gong, 2008). Thus, the TauWT model
allows an assessment of effects of ICV-STZ on a version of tau that is increased in AD and more
prone to AD-related changes (Barghorn & Mandelkow, 2002). Effects of ICV-STZ in TauWT
mice were compared with control littermates expressing mouse tau, as well as with TauP301L
mice, the most commonly used tau model of AD. Whereas the pathology in ICV-STZ treated
TauWT mice was not anticipated to be as severe as that in ICV-STZ treated TauP301L mice, it
was expected to be more advanced than treated controls because of the presence of human 4R tau
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in TauWT mice. It was also predicted that memory deficits will correspond with levels of tau
phosphorylation.
Modeling AD Using Intracerebroventricular Streptozotocin Infusions
Many models of AD use intracerebroventricular infusions of streptozotocin (ICV-STZ) to
induce the following changes witnessed in human AD: an insulin resistant brain state, a
decrement in brain glucose and energy metabolism, cognitive decline, cholinergic deficits, and
oxidative stress. Insulin is a vital hormone for carrying out day-to-day processes. Problems with
insulin in the brain, as witnessed in AD (Aviles-Olmos, Limousin, Lees, & Foltynie, 2013;
Schubert et al., 2004) and induced by ICV-STZ (Grünblatt et al., 2007; Hoyer & Lannert, 2008;
Salkovic-Petrisic & Hoyer, 2007), lead to a decrement in brain glucose and energy metabolism in
which glucose cannot properly fuel cognitive functions. This decline in cognitive functioning is
a prominent feature of AD and can be replicated by an ICV-STZ model. Glucose also plays a
role in the regulation of acetylcholine (Loubatières-Mariani, Chapal, Alric, & Loubatières,
1973), a neurotransmitter implicated in learning and memory (Hasselmo, 2006). In AD and
ICV-STZ models, acetylcholine levels are decreased compared to healthy controls (Blokland &
Jolles, 1994; Bowen, Smith, White, & Davison, 1976; Davies & Maloney, 1976; Hellweg et al.,
1992; Perry, Perry, Blessed, & Tomlinson, 1977). Lastly, oxidative stress, an imbalance between
reactive oxygen species and chemicals that can break them down, is another damaging effect of
AD emulated by an ICV-STZ model (Mao, 2013; Sharma & Gupta, 2001; Shoham, Bejar,
Kovalev, & Weinstock, 2003). The preceding changes are described in detail below.
Insulin Resistant Brain State
Insulin and insulin-like growth factors promote the uptake, oxidation, and storage of
glucose (Bingham et al., 2002), a main energy source of the body. Insulin receptors are
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extensively expressed in the brain (Schubert et al., 2004) and have a high density in the
hippocampus (Unger et al., 1989; Wickelgren, 1998) and cerebral cortex (Wickelgren, 1998),
areas that are important for learning and memory and exhibit extensive AD pathology (Lalonde,
Dumont, Staufenbiel, Sturchler-Pierrat, & Strazielle, 2002). Insulin plays a role in modulating
many cognitive functions including learning, memory, and synaptic plasticity (Zhao, Chen,
Quon, & Alkon, 2004).
In some disease states, the body can no longer appropriately respond to insulin. The
result, insulin resistance, prevents the body from accessing its stores of glucose. In other words,
the body loses its sensitivity to insulin, and insulin no longer effectively lowers blood glucose
levels (Shanik et al., 2008). Insulin resistance may impede the uptake of glucose as well as the
ability of insulin to stimulate its receptors in the brain (Messier & Teutenberg, 2005). An insulin
resistant brain state has since been implicated in the pathogenesis of both AD and Parkinson’s
disease, another neurodegenerative disorder (Aviles-Olmos et al., 2013; Schubert et al., 2004).
In AD, there is a decrease in insulin levels in the brain (Frӧlich et al., 1999; Chen et al.,
2012). Furthermore, insulin, insulin-like growth factor 1, and insulin-like growth factor 2
receptor expression decline with the progression of AD (de la Monte & Wands, 2008). That is,
expression of these receptors decreases as the stage of pathology increases. Insulin also plays a
role in regulating the insulin signaling cascade, alterations of which can induce tau
phosphorylation (Ho et al., 2004). Normal or increased levels of cerebral insulin and insulin-like
growth factor 1 down-regulate GSK-3β (Hong & Lee, 1997), a kinase that is responsible for
phosphorylating tau (Plattner et al., 2006). When this insulin signaling pathway is disturbed,
higher levels of GSK-3β lead to greater tau phosphorylation (Connell et al., 2001).
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ICV-STZ is an appropriate way to induce brain insulin system dysfunction as seen in AD
(Grünblatt et al., 2007; Hoyer & Lannert, 2008; Salkovic-Petrisic & Hoyer, 2007). Following
ICV-STZ administration, there is a dramatic decrease in insulin receptor expression in the
hippocampus along with a significant increase in tau phosphorylation (Grünblatt et al., 2007). It
is likely that this increase in tau phosphorylation is related to the over-activation of GSK-3β due
to decreased phosphorylation at Ser9 (the serine at the ninth amino acid position) caused by the
impaired insulin signaling pathway (Deng et al., 2009). GSK-3β is a proline-directed
serine/threonine kinase that readily phosphorylates tau at many of the phosphorylation sites
implicated in AD (Plattner et al., 2006).
Decrement in Brain Glucose/Energy Metabolism
Glucose provides both the body and, in particular, the central nervous system with the
biological energy needed to carry out its various functions (Sokoloff, 1980). All bodily
processes, including those in the central nervous system (Gibbs, Gibbs, Lennox, & Nims, 1942;
Pardridge, 1983), are supported by the metabolism of glucose. Glucose/energy metabolism in
the brain is antagonistically controlled by insulin (Hoyer, 1996), so it is not surprising that
decreases in insulin correspond with deficiencies in this system as well.
The parietotemporal and frontal areas of the brain, which have high demands for glucose,
as well as heightened sensitivities to insulin, develop early abnormalities in brain glucose/energy
metabolism in AD (Correia et al., 2011; Henneberg & Hoyer, 1995; Hoyer, 2002; Hoyer, 2004).
In early stages of AD, cerebral glucose utilization drops by 45% (Hoyer & Nitsch, 1989) and the
production of adenosine triphosphate (ATP), a molecule used to transport chemical energy for
metabolic processes, from glucose is cut in half (Mattson et al., 2001).
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ICV-STZ administration results in long-term glucose/energy metabolism deficiencies
(Hoyer, Henneberg, Knapp, Lannert, & Martin, 1996). ICV-STZ, which has debilitating effects
on brain glucose metabolism without perturbing basal blood glucose levels (Salkovic-Petrisic,
Tribl, Schmidt, Hoyer, & Riederer, 2006), precipitates abnormalities in glucose/energy
metabolism in numerous regions in the frontal, parietal, sensory, and entorhinal cortices (Duelli,
Schröck, Kuschinsky, & Hoyer, 1994). Following ICV-STZ in rats, reduced glucose utilization
has been found in over a dozen brain areas, most notably in the frontal cortex and in all
hippocampal subfields (Duelli et al., 1994). Similar to what is witnessed in AD, there is a
decrease in activity of glycolytic enzymes (chemicals which facilitate glycolysis) in the
hippocampus (Plaschke & Hoyer, 1993). In fact, glucose and glycogen metabolism falls by 10 to
30% in rats receiving ICV-STZ (Plaschke & Hoyer, 1993).
Cognitive Decline
Progressive cognitive decline is a prominent feature of AD (Albert et al., 2011). Memory
deficits, including those in working (Miller, 1971; Morris, 1984; Kopelman, 1985) and semantic
(Chertkow & Bub, 1990; Martin & Fedio, 1983; Weingartner, Grafman, Boutelle, Kaye, &
Martin, 1983) memory types, comprise the most characteristic consequence of AD (Sjӧgren,
Sjӧgren, & Lindgren, 1952). Individuals with AD perform poorly on tests of semantic memory,
such as picture naming or word finding, and these memory deficits become more profound as
AD progresses (Hodges, Patterson, Oxbury & Funnell, 1992). Patients with AD are also known
to get lost in familiar surroundings, partially impacted by visuospatial disorientation (Henderson,
Mack, & Williams, 1989).
ICV-STZ results in progressive declines in cognitive functioning resembling those
observed in AD (Grünblatt et al., 2007; Salkovic-Petrisic & Hoyer, 2007). Rats that receive
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ICV-STZ show deficits in learning and memory (Hoyer & Lannert, 1999; Lannert & Hoyer,
1998). In particular, ICV-STZ causes impairments in working and reference memory (Lannert
& Hoyer, 1998), passive avoidance learning (Mayer, Nitsch, & Hoyer, 1990), and spatial
discrimination (Blokland & Jolles, 1993; Blokland & Jolles, 1994).
Cholinergic Deficits
In addition to abnormal cerebral glucose utilization and energy metabolism, various
neurotransmitter systems have been implicated in the progression of AD. Synthesis of
acetylcholine, an important neurotransmitter for learning and memory (Hasselmo, 2006),
decreases in the AD brain (Sims et al., 1980). Early stages of AD are accompanied by the
degeneration of cholinergic nuclei in the basal forebrain as well as their projections in nearly all
cortical areas (Whitehouse, Price, Clark, Coyle, & DeLong, 1981). The degeneration of
cholinergic neurons leading to instabilities in serotoninergic, noradrenergic, and dopaminergic
systems is correlated with the progression of cognitive decline in AD (Baskin et al., 1999; Wang
et al., 2007). Analysis of postmortem brain samples of AD patients has found a significant
decrease in cholinergic neurons (Bowen et al., 1976; Davies & Maloney, 1976; Perry et al.,
1977). It is also worth noting that one of the key components of acetylcholine, acetyl-CoA, is
controlled by glucose/energy metabolism (Gibson, Jope, & Blass, 1975). Because there is a
decrement in glucose/energy metabolism in AD, corresponding reductions in acetyl-CoA may
explain the vulnerability in the cholinergic system (Wurtman, 1992).
ICV-STZ causes cholinergic system dysfunctions (Blokland & Jolles, 1994; Hellweg et
al., 1992). One week after ICV-STZ administration, activity of choline acetyltransferase, an
enzyme needed to synthesize acetylcholine, is reduced in the hippocampus (Blokland & Jolles,
1994; Hellweg et al., 1992). ICV-STZ also increases activity of the enzyme that breaks down
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acetylcholine, acetylcholinesterase (Agrawal, Tyagi, Shukla, & Nath, 2009; de la Monte, Tong,
Lester-Coll, Plater, & Wands, 2006), further exacerbating its reduced presence in the brain.
Interestingly, the reduced presence of choline acetyltransferase in the hippocampus is correlated
with impaired spatial discrimination ability as measured in the MWM (Blokland & Jolles, 1994).
Oxidative Stress
New evidence suggests that oxidative stress may occur before the earliest symptoms of
AD (Mao, 2013). The brain is disproportionately susceptible to oxidative stress because of its
high oxygen consumption and lipid content coupled with relative scarcity of antioxidant enzymes
(Coyle & Puttfarcken, 1993). Cerebral mitochondria, the organelles in cells that are mainly
responsible for generating energy-rich ATP, are structurally damaged in the brains of individuals
with AD (Hirai et al., 2001). Damage to the mitochondria results in the release of free radicals,
which are implicated in causing oxidative stress (Smith et al., 1996). Oxidative stress has been
associated with several neurodegenerative disorders, including Parkinson’s disease, amyotrophic
lateral sclerosis (ALS), and AD (Markesbery, 1997).
In an ICV-STZ model, oxidative stress precedes memory deficits (Sharma & Gupta,
2001; Shoham, Bejar, Kovalev, Schorer-Apelbaum, & Weinstock, 2007). Alkylating properties
of STZ produce reactive oxygen species that eventually lead to neurodegeneration and DNA
damage (Lester-Coll et al., 2006). An increase in free radicals combined with a decrease in
glutathione, an important antioxidant responsible for reacting with free radicals, correlates with
greater levels of oxidative stress in an ICV-STZ model of AD (Sharma & Gupta, 2001). Lipid
peroxidation, a gauge of free radical production, also increases in this model (Sharma & Gupta,
2001).
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Together, these studies suggest that an ICV-STZ model is an ecologically valid method to
induce the biochemical and behavioral effects seen in AD.
Testing of Spatial Memory Using the Barnes Maze
In AD, some of the earliest changes in tau pathology affect the hippocampus, a brain
region important in learning and memory (Altman & Das, 1965; Kaplan & Hinds, 1977).
Because AD has profound effects on the hippocampus (Arriagada, Growdon, Hedley-Whyte, &
Hyman, 1992; Hof et al., 1992; Morris & Fulling, 1988), it is important to use a test that is
sensitive to alterations in hippocampal-dependent memory. In order to assess effects of ICVSTZ administration on the hippocampus, hippocampal-dependent memory test was administered.
Although there are several different tests widely used to evaluate hippocampal-based learning
and memory in animal models, the Barnes maze is best suited for this study given the ability to
test the brain region of most interest with fewer disadvantages than other comparable
assessments. The rationale for using the Barnes maze, as opposed to other hippocampaldependent memory tests, is discussed below.
There are four commonly used hippocampal-dependent memory tests: the Morris water
maze (MWM; Gerlai, 2001), fear conditioning (Burman & Gewirtz, 2007; Gerlai, 2001), radial
arm maze, and Barnes maze (Barnes, 1979). In the MWM, mice must locate a hidden platform
in a large tank of water (Morris, 1984). The mice use distal cues to learn the spatial location of
the escape platform. The accurate directionality of swimming paths in the MWM, despite the
hidden platform, indicates that spatial learning is indeed assessed (Morris, 1984). The contextual
fear conditioning task and trace fear conditioning task, other tests of hippocampal-dependent
learning and memory (Burman & Gewirtz, 2007; Gerlai, 2001), use cue recognition (contextual)
or temporal discrimination (trace) to predict the presence of a shock. The radial arm maze
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involves placing food at the ends of the arms of a maze and having a food-restricted animal find
the food as efficiently as possible given the extra-maze cues (Meck, Church, & Olton, 1984).
Re-visiting arms where the food has already been eaten indicates a dysfunction in spatial
memory. Lastly, the Barnes maze is a large circular platform with many holes around the
perimeter in a brightly-lit room. One of the holes allows the mice to exit the maze and hide in a
dark box, relying on a tendency for mice to choose dark, enclosed spaces over open, brightly lit
ones (Harrison, Reiserer, Tomarken, & McDonald, 2006). Mice can utilize extra-maze cues to
locate the escape box as quickly as possible. Induced hippocampal lesions correlating with
hindered performance on the MWM (Logue, Paylor, & Wehner, 1997) and fear conditioning task
(Logue et al., 1997) confirm their validity as measures of hippocampal-dependent memory, and
the preceding analogous tests have been developed using the same reliance on spatial learning
and memory. Although all of the preceding tests assess spatial learning and memory, different
motivational factors, motor behaviors, and environmental conditions differentiate them (Gerlai &
Clayton, 1999).
Of these four different tests of hippocampal-dependent learning and memory, the MWM
is the most widely used (Vorhees & Williams, 2006). Through extensive testing in the past few
decades, the ability of the MWM to assess hippocampal-dependent spatial navigation and
reference memory has been confirmed (Vorhees & Williams, 2006). It is also relatively
impervious to species and strain differences, and reliable despite variances in tank configurations
and testing procedures (Vorhees & Williams, 2006). The MWM also has its own share of
disadvantages. Repeatedly removing the mice from the water tank results in slight hypothermia.
Because hypothermia causes tau phosphorylation (Planel et al., 2004; Planel et al., 2007), the
practicality of using this test with tau mice is limited. Furthermore, the MWM (Dudchenko,
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Goodridge, Seiterle, & Taube, 1997) employs an aversive stimulus. The stress induced by these
tests may result in unintentional tau phosphorylation because kinases that phosphorylate tau are
activated by stress (Goedert et al., 1997).
Contextual and trace fear conditioning tasks are other valuable measures of hippocampaldependent memory. Like the MWM, these tests do not require extensive pre-training and can be
used as a test of both nonspatial and spatial learning (McEchron, Bouwmeester, Tseng, Weiss, &
Disterhoft, 1998). However, fear conditioning tasks also use an aversive stimulus (Phillips &
LeDoux, 1992), resulting in an increase of stress-related hormones (Daviu, Delgado-Morales,
Nadal, & Armario, 2012).
The radial arm maze is beneficial in that it does not employ an aversive stimulus; rather,
food is used as a reinforcer (Hodges, 1996). However, using food as a reinforcer is a possible
confounding variable between the ICV-STZ and control mice. Following ICV-STZ infusion, the
threshold for lateral hypothalamic self-stimulation is lowered, suggesting that reward circuitry in
the brain is sensitized to electrical impulses (Carr, Kim, & Cabeza de Vaca, 2000). Given that
food is another stimulus known to activate the brain’s reward pathway (Lobo, 2012), it was
possible that the ICV-STZ mice would differentially respond for food compared to the control
mice. Also, in order for food to effectively serve as a reinforcer, the mice must have restricted
diets or be maintained below their free-feeding weight, which is potentially dangerous for mice
with insulin and glucose metabolism deficiencies. There is additional evidence that suggests that
hypoglycemia-induced binge feedings may affect body composition (McNay et al., 2012).
The Barnes maze is particularly useful because it does not use a food as a reinforcer.
Because implementing a test with a food reinforcer is not feasible for the reasons mentioned
above, it is necessary to select a test that relies on a different kind of reinforcer. Although the
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fan used in the Barnes maze is aversive, the stress it induces is negligible compared that of the
MWM or fear conditioning task. For example, the MWM results in greater increases in plasma
corticosterone, a biological indicator of stress, than the Barnes maze (Harrison, Hosseini, &
McDonald, 2009). A potential downfall of the Barnes maze is its sensitivity to strain differences.
For instance, different mouse strains have been shown to react differently to the presence of
various stimuli (Youn et al., 2012). It is possible that particular genetic factors of the strains
used in this experiment would result in the mice spending more or less time to escape the fans
and lights, and thus invalidating the measures used to test memory (Nguyen, Abel, Kandel, &
Bourtchouladze, 2000). For the purpose of this experiment, the advantages of the Barnes maze
outweigh its disadvantages. Neither the TauP301L nor TauWT lines have been previously
evaluated in the Barnes maze. However, previous studies suggest PS19 mice, which overexpress
human tau (1N4R) containing the P301S mutation found in FTDP-17, exhibit deficits in spatial
learning and memory as assessed by the Barnes maze (Brunden et al., 2010). Given the
particular limitations of the MWM, fear conditioning task, and radial arm maze for this model,
the Barnes maze was implemented in this study. The unique combination of advantages and
disadvantages present in the Barnes maze made it best-suited for the unique challenges of this
particular experiment given that the Barnes maze minimizes corticosterone spikes (Harrison et
al., 2009), food deprivation, and hypothermia.
Statement of the Problem
Alzheimer’s disease (AD) is a common neurodegenerative disorder affecting millions of
people with no known cause or cure. It is characterized by the presence Aβ plaques and NFTs
composed primarily of tau, a microtubule-binding protein (Kolarova et al., 2012). Late-stage
AD ends with profound neuronal loss. To date, most research has focused on the role of Aβ in
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initiating the disorder; however, clinical trials using Aβ-modifying drugs have failed to slow or
halt the progression of the disease, despite successfully decreasing Aβ levels (Small & Duff,
2008). Thus, it is necessary to investigate other potential etiologies, including abnormalities in
the tau protein.
Tau, a protein in the brain responsible for microtubule nucleation and stabilization
(Eckermann et al., 2007), aggregates into the pathological NFTs seen in AD. Tau pathology
alone is capable of causing the neurodegeneration found in sporadic and familial tauopathies
(Sorrentino & Bonavita, 2007), and the aberrant phosphorylation of tau is an essential
neuropathological event in AD (Kolarova et al., 2012). The mechanisms by which tau is
hyperphosphorylated are not fully understood, but numerous metabolic abnormalities, such as a
decrease in insulin levels in the brain (Frӧlich et al., 1999) and a drop in cerebral glucose
utilization (Hoyer & Nitsch, 1989), are present in AD and result in tau phosphorylation (de la
Monte, 2012).
Recent advancements made in AD mouse models allow for the pathological role of tau to
be better evaluated. Mice expressing mutant human tau, referred to as TauP301L, have a
transgene with a proline-to-leucine mutation at the 301st amino acid found in frontotemporal
dementia with parkinsonism-17 (FTDP-17), another tauopathy (Orr, Pitstick, Canine, Ashe, &
Carlson, 2012). Although the mutation is found in FTDP-17, TauP301L mice are generally
considered a mouse model of AD because (1) use of a CaMKII promoter restricts pathology to
brain regions implicated in AD (i.e., the forebrain) and (2) the mutation, when restricted to the
forebrain, results in formation of NFTs, neuronal death, and progressive memory loss as
observed in AD (Ramsden et al., 2005). Finally, TauWT mice are another valuable mouse
model because they express the 4R version of human (rather than rodent) tau without a genetic
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mutation. These mice allow for the manipulation of variables that may precipitate AD and
subsequent evaluation of tau pathology. TauWT mice can also serve as controls for the
overexpression of human tau in mice to yield support for the assumption that any memory
deficits or pathological changes are attributable to alterations in tau (e.g., tau
hyperphosphorylation) and not the overexpression of human tau per se.
ICV-STZ was administered to both the TauP301L and TauWT mice, as well as littermate
controls, to emulate the early metabolic changes found in the AD brain. By doing so, it was
anticipated that a more ecologically valid mouse model of AD would be developed using the
TauWT mice that does not rely on genetic mutations.
Method
Subjects and Treatments
In total, 56 male mice were used (Figure 1A). These mice had unrestricted access to food
and water and were group housed in a temperature- and humidity-controlled colony room with a
12-hour light/dark cycle.
The generation of TauWT and TauP301L mice has been described extensively in the past
(Hoover et al., 2010; Ramsden et al., 2005; SantaCruz et al., 2005). Briefly, mice expressing
mutant human four-repeat tau lacking the N-terminal sequences (4R0N), referred to as
TauP301L, were created by crossing responder and activator lines. Responder mice on the
FVB/N background, heterozygous for the Tetracycline Response Element (TRE)-TauP301L
transgene, are bred with activator mice on the 129S6 background, heterozygous for the tet-off
tetracycline transactivator (tTa) reading frame downstream of a Ca2+-calmodulin (CaMKII)
promoter element (SantaCruz et al., 2005). The breeding of heterozygous responder and
activator mice produces four genotypes with the following nomenclature, TauP301L/CKtTA,
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and encompasses what is referred to as the TauP01L mice (+/+) and Controls (-/+, +/-, -/-). To
limit the variability introduced by tTa expression, only activator positive mice (-/+) were used as
controls. No behavioral differences exist between the three control groups, and human tau is not
expressed (Hoover et al., 2010; Ramsden et al., 2005; Santacruz et al., 2005). TauWT mice were
produced in the same manner, with the exception that TauWT mice express 4R0N human tau
without the P301L mutation.
In TauP301L and TauWT mice, the expression of human tau is limited to the forebrain
with a CaMKII promoter and controlled through the use of a tetracycline transactivator (tTa)
protein (Ramsden et al., 2005). TauP301L mice have a proline-to-leucine mutation at the 301st
amino acid found in frontotemporal dementia with parkinsonism-17 (FTDP-17), another
tauopathy (Orr, Pitstick, Canine, Ashe, & Carlson, 2012). Although the mutation is found in
FTDP-17, the pathology in TauP301L mice is restricted to areas of the brain that are affected by
AD (i.e., the forebrain) by the CaMKII promoter. The mutation, when restricted to the forebrain,
results in formation of NFTs, neuronal death, and progressive memory loss as observed in AD
(Ramsden et al., 2005). Approximately half of the controls were (-/+) littermates of the TauWT
mice and half were (-/+) littermates of the TauP301L mice. To control for differences in
transgene copy number, which can affect transgene expression (Kong et al., 2009), no more than
two mice of the same transgene [Tg; i.e., (-/+) or (+/+)] from one litter were assigned to the same
treatment condition.
The tet-off system allowed for regulatable expression of tau protein with the use
doxycycline (Figure 1B). In the tet-off system, the presence of doxycycline prevents the
transcription of tau by preferentially binding to the TRE. In the absence of doxycycline,
transcription occurs when the tTa protein binds to the TRE. During conception until 2 months of
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age, the mice received water with 40 parts per million (ppm) doxycycline hyclate to suppress tau
expression during development (Figure 2C; Liu, Wang, Brenner, Paton, & Kasparov, 2008).
Dams were placed on doxycycline water 2 weeks prior to breeding, and experimental offspring
continued doxycycline until they were approximately 2.5 months of age. On the day of the
surgery, doxycycline water was replaced with regular water and transcription of tau was allowed
to occur for approximately 3.5 months (SantaCruz et al., 2005). All experimental procedures
were approved by the West Virginia University Animal Care and Use Committee.
Surgery and ICV-STZ Administration
On the same day mice were removed from doxycycline, mice received either a single,
bilateral infusion of ICV-STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose); 3
mg/kg; 2.5 µl/side) dissolved in 0.05 M citrate vehicle (pH 4.5) or vehicle (citrate buffer) into the
lateral ventricles. Sterile conditions were maintained during surgeries. After induction with 5%
isoflurane for 3 min, the mice were injected subcutaneously with 1 mg/kg ketoprofen, 1mg/kg
bupivacaine, and 3 mg/kg sterile saline. The fur in the surgical site was clipped and shaved, the
area was cleaned with alternating 70% isopropyl and iodine, and a 2 cm longitudinal incision
was made at the skull midline. The infusions were performed while the mice were anesthetized
with 2-4% isoflurane and placed into a stereotaxic device. Coordinates of the infusions, based
off of bregma, were ±1.0 mm lateral, -0.5 mm posterior, and -2.5mm ventral (Coomans, De
Rydt, & Van Proeyen, 2011). To facilitate the flow of the infusion into the brain, the syringe
was slowly pulled up through the ICV from -2.5mm to -2.2mm. Microinfusion of STZ or
vehicle was controlled by a GenieTouch Syringe Pump (Kent Scientific, Connecticut, USA).
Twenty-eight gauge injectors were attached to 25 µl Hamilton syringes to deliver STZ or vehicle
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at a steady rate of 1 µl/min for 2.50 min per side with an additional 5 min for diffusion. The
holes in the skull were filled in with bone wax and the incision was closed with surgical glue.
Immediately following surgery, the mice were removed from anesthesia, placed into a
cage half-covered with a heating pad, and examined closely for appropriate respiration patterns
and the return of reflexes. The mice remained alone in this post-operative cage for 30 min. For
at least one hour after surgery, the mice were monitored for signs of distress and the ability to
ambulate before being returned to the colony in cages with no more than three mice. On postoperative days 1, 2, and 3, 3 mg/kg sterile saline and 1 mg/kg ketoprofen were injected
intraperitoneally and subcutaneously, respectively, to alleviate discomfort. Mice also received
moist chow during this period. After post-operative day 3, the mice were allowed to return to
their original cage.
Barnes Maze
At approximately 5.5 months of age (Figure 1C), the mice began the first of two
habituation days for behavioral testing, which immediately preceded the five acquisition days
and two probe trials.
Apparatus. The Barnes maze is a large, flat, white platform (diameter=122 cm) with
forty holes (diameter=5 cm) equally spaced around the perimeter. The platform was raised
approximately 108 cm above the ground. Between every trial, the maze was cleaned with a 35%
ethanol solution. A Logitech HD Pro Webcam C920 (Romanel-sur-Morges, Switzerland)
camera mounted above the platform recorded all trials using Logitech Webcam software.
Recorded trials were later viewed by a blinded experimenter, and slowed-down or repeated as
necessary, to assess for the variables of interest.
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Habituation. For the two days preceding acquisition trials, the mice were habituated to
the maze. In this stage, the spatial cues around the room were not present, the fans were turned
off, and the room light was turned on. On Day 1 of habituation, the mice were placed on the
platform next to its respective escape hole under a transparent, plastic breaker. The mice were
able to explore the escape box and the area immediately surrounding it, but were not able to
access the rest of the maze. This allowed the mice to learn how to access the escape box
underneath the platform. After 5 min, the mice were returned to its home cage. The mice were
each subjected to two trials of this procedure with about 25 min between trials. On Day 2 of
habituation, the mice began in the center of the platform under a transparent, plastic beaker.
After 10 s, the beaker was raised and the mice were gently guided to the escape box in the target
hole. Once the mice entered the box, the hole was covered for 2 min. After the 2 min had
elapsed, the mice were returned to its home cage. The two stages of habituation ensured that the
mice learned how to access the escape hole, and that the escape hole could be found from the
center of the platform to escape from the aversive stimuli. The mice each completed two trials
on habituation Day 2 and there was approximately 25 min between trials.
Acquisition. The acquisition phase took place on Days 3 through 7. Under one hole, a
small, dark recessed chamber, referred to as the escape box, was attached to the bottom of the
platform. The escape box was accessible by entering the target hole. The room light was turned
on straight above the maze, fans were directed at the platform from four sides, and spatial cues
were placed around the room. The escape box was placed in the same hole for each trial relative
to extra-maze spatial cues placed on the walls of the room. Although the maze was cleaned with
ethanol between each trial, it was also rotated around its central axis to control for possible
remaining odor cues. After rotation, the escape box was realigned with the extra-maze cues.
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The mice began the trial under a transparent, plastic beaker in the center of the platform. After
10 s, the beaker was raised and the mice were free to find the escape box. The trials ended 30 s
after the mice entered the escape box. If the mice did not enter the escape box during the 3 min
trial, the experimenter gently guided the mice into it and covered the hole for 30 s. The mice
were each subjected to three trials on each day with approximately 20 min between trials.
The following variables were assessed during the acquisition trials: hole deviation, total
errors, total latency, primary errors, primary latency, and search strategy. For each of these
variables, an encounter with a hole was defined as the mice sticking their entire heads into the
hole. The hole deviation was measured by determining how many holes were between the target
hole and first hole the mice encountered on the platform. Total errors included the number of
holes the mice encountered before entering the escape box, and total latency included the total
time before the mice entered the escape box. Total errors and latency may be confounded by the
tendency of some mice to explore the maze even after initially locating the hole (Harrison et al.,
2006). With this in mind, primary errors and primary latency were also used. Primary errors
included the number of holes that the mice encountered before dipping its head into the target
hole and primary latency was the time lapse between the beginning of the trial and the first
encounter with the target hole. Lastly, there were three different search styles: random, serial,
and spatial. Random was a nonsystematic searching strategy characterized by multiple crossings
through the center of the platform or inability to find the target hole. A serial search strategy
involved encounters with three consecutive holes around the edge of the platform. Finally, a
spatial search strategy was used when mice rely on extra-maze cues to navigate directly within
two holes of the target hole.
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Probe. The first of two probe trials took place 24 h after the last acquisition trial. The
second probe trial was one week following the first. The escape box was removed for the probe
trials. The mice were placed into a transparent, plastic beaker at the center of the platform.
After 10 s, the beaker was removed and the mice were free to search the maze. In addition to
total session time (90 s), three 30 s bins were also evaluated Probe trials lasted 90 s with three
bins: 0-30 s, 31-60 s, and 61-90 s. It was expected that the response of head pokes into the target
hole would begin to be extinguished in the 31-60 s and 61-90 s bins as the mice search for the
box without being able to locate the correct hole. The variables measured during the probe trials
included the time spent to reach the target hole where the escape box was previously hidden, the
number of encounters with the target hole per bin, and the number of encounters with each error
hole per bin.
Glucose Testing
One day after the last probe trial of Barnes maze testing, fasting blood glucose readings
were obtained from the mice to ensure no peripheral effects of ICV-STZ treatment. All food was
removed from the cages in the morning, and 5.5 hours later, testing took place. To obtain a
blood sample, the mice were first restrained in a 50 ml conical vial with drilled air holes, and the
upper thighs of the mice were shaved with electric clippers and cleaned with 70% alcohol. A 27gauge needle was used to puncture the saphenous vein, and a TRUEresult Blood Glucose
Monitoring System with TRUEtest Blood Glucose Test Strips (Nipro Diagnostics, Osaka, Japan)
was used to provide a reading.
Antibodies
To assess progression of tau pathology, antibodies with differential abilities to detect
stage-specific, biochemical changes in tau were used after the mice had been euthanized (Table
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1; Chai et al., 2011). Tau-5 (Invitrogen, Carlsbad, CA) recognizes both human and mouse tau
and serves as a general marker for tau, independent of pathology. MC-1 and CP-13 detect
conformation- and phosphorylation-specific epitopes, respectively, in the earliest stages of AD
pathology. PG-5 identifies changes in tau related to mid-stage tau pathology, including
pretangles (the accumulations of nonargyrophilic hyperphosphorylated tau) in the neuronal cell
body. Lastly, Alz-50 and PHF-1 identify conformational changes in tau and paired helical
filaments indicative of late-stage tau pathology. MC-1, CP-13, PG-5, Alz-50, and PHF-1 were
generous gifts from Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY). Blots
were normalized with actin (Santa Cruz Biotechnology, Dallas, TX) to control for variations in
loading. To investigate pathological changes in tau, the steps described below were used.
Dissection and extraction of mouse hippocampus. Two days after the conclusion of
Barnes maze testing, all mice were euthanized. Brains were immediately removed and separated
into the olfactory bulbs, the cerebellum, the prefrontal cortex (PFC), the hippocampi, and the
remaining forebrain hemispheres, immediately frozen on dry ice, and then stored in the freezer at
-80 C. The hippocampi were placed into 200 µl sucrose buffer (10 mM HEPES, 0.32M sucrose
added the day of use, 40 mM β-glycerophosphoate, 20 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, 30 mM NaF, 1 mM EDTA, 1 mM EGTA, 15 µM calpeptin, pH 7.4) with
protease inhibitors (cOmplete ULTRA tablets, mini, EDTA-free, Roche diagnostics, Laval, QC,
Canada) and phosphatase inhibitors (phosSTOP EASYpack, Roche diagnostics, Laval, WC,
Canada) added fresh the day of extraction. To homogenize the tissue, the hippocampus was
passed through a one milliliter (ml) syringe without a needle five times. The tissue was then
passed through a syringe with a 20-gauge needle 20 times, and then further dissociated by
passing it through a 27-gauge needle five times. The tissue lysate was centrifuged for 10 min at
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1,000 x g at 4 C, and the resulting supernatant was collected and centrifuged again for 6 min at
1,000 x g. Once again, the supernatant was centrifuged at 12,000 x g for 20 min, the resulting
pellet was discarded, and the supernatant was stored at -80 C. Protein concentrations in each
sample were determined by performing a bicinchoninic acid (BCA; Thermo Scientific,
Rockford, IL) protein assay using bovine serum albumin (BSA; Sigma, St. Louis, MO) as a
standard. To adjust the samples so that they had protein concentrations in the BCA linear range,
the samples were diluted 1:5 with fresh sucrose buffer with added protease and phosphatase
inhibitors and then frozen at -80°C.
Western blotting. After the diluted hippocampal tissue samples were thawed, equal
amounts of protein were aliquoted and mixed with loading buffer (450 mM Tris HCl, pH 8, 8%
SDS, 24% glycerol, 5% β-mercaptoethanol, 0.1% bromophenol blue, 0.1% phenol red). Samples
were then heated to 95 C for 5 min, separated on 8% or 8—16% Tris-HCl sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad, Hercules, CA), and
transferred onto 0.45 µm polyvinylidene difluoride membranes (Millipore, Bedford, MA).
Membrane blots were blocked for one hour at room temperature in 5% BSA in 0.1% Tween
20/Tris-buffered saline (TTBS; 396 mM NaCl, 20 mM Trizma base, pH 7.4). After blocking,
membranes were incubated with an antibody directed against the site of interest (Table 1) in 5%
BSA in TTBS either for one hour at room temperature or overnight at 4C. After washing the
membranes with TTBS four times for 5 min each, they were incubated with an HRP-coupled
secondary antibody (GE Healthcare, Buckinghampshire, UK) in TTBS for 2 hours at room
temperature. All blots contained a consistent loading control and were stripped with Restore
Western Blotting Stripping Buffer (Thermo Scientific, Rockford, IL) and re-probed with actin
(Santa Cruz Biotechnology, Dallas, TX) to ensure equal loading of samples within and across
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blots. Actin blots were incubated with an AP-coupled secondary antibody (Santa Cruz
Biotechnology, Dallas, TX) and immunofluoresced with Lumi-Phos (Thermo Scientific,
Rockford, IL).
Immunoreactive bands were visualized by enhanced chemiluminescence with either
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) for HRPconjugated secondaries or Lumi-Phos (Thermo Scientific, Rockford, IL) for AP-conjugated
secondaries. Band density was measured using a FluorChem E Imager (Protein Simple, Santa
Clara, CA). All blots were quantified using Alphaview (Protein Simple, Santa Clara, CA). Using
various exposure lengths, the loading control band on different blots of the same antibody was
matched within 10% across blots. Both tau and actin bands were quantified as the average pixel
values in the region. To account for unequal loading during western blotting, the pixel values of
the tau bands were divided by the pixel values of the actin bands of the same samples.
Statistical Analyses
Assumptions regarding normality, homogeneity of variance, and independence of errors
were assessed and met. Variables of interest during the acquisition trials of the Barnes maze test
(i.e., hole deviation, primary errors, primary latencies, total errors, and total latencies) were
evaluated using two-way repeated-measures analyses of variance (RMANOVAs) with the day as
a within-subjects factor and transgene (Tg: Control, TauWT, or TauP301L) and treatment
condition (Tx: ICV-vehicle or ICV-STZ) as between-subjects factors. Variables of interest
during the probe trials of the Barnes maze (i.e., time spent to reach the target hole, the number of
encounters with the target hole per bin, and the number of encounters with each error hole per
bin) were examined using two-way analyses of variance (ANOVAs) with Tg and Tx condition as
the between-subjects factors. Search strategy was assessed using chi-square tests.
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Immunoblotting was also analyzed with two-way ANOVAs with Tg and Tx conditions as
between-subjects factors. Bonferroni post-hoc tests followed all significant analyses. For all
tests, statistical significance was defined as α=.05. Reported statistics are the mean ± standard
error of the mean (SEM).
Results
Physiological Parameters
Figure 2A shows fasting blood glucose levels taken on the day between the conclusion of
behavioral testing and euthanasia. There were no differences among treatment (Tx) and
transgene (Tg) groups [Tx: F(1,33)=1.07, p=.31; Tg: F(2,33)=1.669, p=.20; Tx*Tg:
F(2,33)=.29, p=.75]. At the time of euthanasia, neither body weights (Figure 2B) nor brain
weights (Figure 2C) differed among the groups [body weight: Tx: F(1,50)=.06, p=.80; Tg:
F(2,50)=1.01, p=.37; Tx*Tg: F(2,50)=1.88, p=.16 and brain weight: Tx: F(1,46)=.51, p=.48;
Tg: F(2,46)=1.74, p=.19; Tx*Tg: F(2,46)=1.18, p=.32].
Behavioral Testing
Acquisition. For hole deviation, the distance of the first hole visited relative to the target
hole, there were no statistically significant improvements across days [Figure 3; Table 2]. For
primary errors (Figure 4A), fewer error hole visits were made as the days progressed [Day:
F(4,200)=12.16, p<.001]. Figure 4B demonstrates the Day*Tg interaction [F(8,200)=2.77,
p<.01]; TauWT mice made significantly more primary errors than the Control mice on Day 1,
but did not differ on any other days. With the exception of the Day*Tg interaction, the number
of primary errors did not differ among Tx or Tg groups (Table 2). Primary latency, the time to
initially locate the target hole, decreased with additional training [Figure 5; Day:
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F(4,200)=80.91, p<.01]. However, neither Tx nor Tg significantly impacted the time required
for the mice to first locate the target hole (Table 2).
Total errors decreased as training progressed [Figure 6; Day: F(4,200)=8.34, p=<.001].
In addition, there was a Day*Tx*Tg interaction [F(8,200)=1.98, p=.05]. The Vehicle-TauP301L
mice did not differ from any other groups until Day 5, at which point the Vehicle-TauP301L
mice made significantly more errors than both the STZ-Control and Vehicle-TauWT mice.
Neither the effect of Tg and Tx group alone, nor the two-way interactions with Day, were
statistically different for total errors (Table 2). For total latency, the mice entered the escape box
more quickly with each subsequent day of acquisition [Figure 7A; Day: F(4,200)=8.34, p<.001].
As shown in Figure 7B, a main effect of Tg was observed [Tg: F(2,50)=3.88, p=.027];
TauP301L mice, regardless of ICV-STZ treatment or Day, took longer to enter the escape box
than the Control mice (p=.03), but not the TauWT mice (p=.16). There were no significant
differences for total latency between Tx groups or interactions (Table 2).
Search strategy for Tg, Tx, and Tg-Tx groups was evaluated using chi-squared tests for
each of the three strategies on Days 1 to 5 of acquisition (Table 3). On Day 1, there was a
significant Tx effect for which the use of a serial strategy was significantly higher in vehicletreated mice than STZ-treated mice [Figure 8A; χ(3)=9.05, p=.03] and also a significant Tx*Tg
effect such that Vehicle-TauWT mice used a serial search strategy more than STZ-Control mice
[Figure 8B; χ(15)=25.84, p=.04].
Probe. For Probe 1 (Table 4), there were no significant Tx*Tg effects for total errors
(Figure 9A), the 31-60 s bin (Figure 9C), or the 61-90 s bin (Figure 9D), but there was a Tx*Tg
effect for 0-30 s bin [Figure 9B; F(2,50)=3.34, p=.04]. Post-hoc analyses indicated that,
although Control and TauWT mice in the ICV-STZ condition did not differ significantly from

STREPTOZOTOCIN-INDUCED MODEL OF ALZHEIMER’S DISEASE

30

their respective transgene groups in the vehicle condition, TauP301L mice in the ICV-STZ
condition made more errors than the TauP301L mice in the vehicle condition in the first time bin
(p=.04). In addition, there was a main effect of Tx (Figure 10) for total errors [F(1,50)=5.49,
p=.02], 0-30 s [F(1,50)=4.39, p=.04], 31-60 s [F(1,50)=3.89, p=.05], and 61-90 s [F(1,50)=5.49,
p=.02]. There was no Tg effect for any of these bins (Table 4). For escape latency in Probe 1,
there were no significant differences (Table 4) among Tg or Tx groups (Figure 11). Escape hole
visits (Figure 12) also did not significantly differ among groups (Table 2) during the total bin
(Figure 12A), 0-30 s bin (Figure 12B), 31-60 s bin (Figure 12B), or 61-90 s bin (Figure 12D).
For Probe 2 error hole visits, there were no Tx*Tg interactions for total errors (Table 4)
in the total bin (Figure 13A), the 0-30 s bin (Figure 13B), the 31-60 s bin (Figure 13C), or the
61-90 s bin (Figure 13 D). There was, however, a significant effect of Tx for errors in the 0-30 s
bin [Figure 14; F(1,50)=4.08, p=.05], but not any of the other bins (Table 2). Escape latency in
Probe 2 did not differ among treatment or transgene groups [Figure 15; Table 4). Escape hole
visits (Figure 16) also did not differ among treatment or transgene groups (Table 4).
Western Blotting
Tau-5, an antibody that detects both mouse and human tau, indicated that total tau levels
in TauWT (p<.001) and TauP301L (p=.002) mice were higher than Controls [Figure 17; Tg:
F(2,34)=11.20, p<.001]. As previously reported (Hoover et al., 2010), TauWT express wild-type
human tau at concentrations equivalent to P301L human tau in rTgP301L mice. ICV-STZ did
not alter tau levels as there were no observed differences between Tx groups [F(1,34)=.21,
p=.65], and there was also no interaction between Tx and Tg [F(2,34)=2.82, p=.07].
Levels of MC-1, specific for a conformational change in tau associated with early-stage
AD pathology, were significantly increased in TauP301L mice [Figure 18; Tg: F(1,35)=3.65,

STREPTOZOTOCIN-INDUCED MODEL OF ALZHEIMER’S DISEASE

31

p=.04] compared to Controls (p=.03), but not TauWT mice (p=0.41). There was neither a
significant main effect of Tx [F(1,35)= 0.00, p=.99] nor an interaction between Tx and Tg
[F(2,35)=.19, p=.83]. Use of CP-13 (Figure 19), an antibody that detects a phosphorylated serine
indicative of early-stage AD pathology, showed significantly different levels among the groups
[F(2,34)=13.82, p<.001]. TauWT mice exhibited significantly higher CP-13 levels than both
Controls (p<.001) and TauP301L (p=.01), but the Control and TauP301L mice did not differ.
There was no main effect of Tx [F(1,34)=1.13, p=.30] or an interaction between Tx and Tg
[F(2,34)=.26, p=.78].
There was no positive staining in any of the groups when probed using PG-5 or Alz-50
antibodies. Positive staining with actin confirms the lack of PG-5 and Alz-50 signal was not due
to inaccurate loading.
Finally, PHF-1, an antibody that detects paired helical filaments, showed a significant
main effect of Tg [Figure 20; F(2,21)=4.18, p=.03] such that the TauP301L mice exhibited
significantly higher levels of paired helical filaments than the Control mice (p=.03), but not the
TauWT (p=1.00) mice. No effect of Tx [F(1,21)=.21, p=.65] or interaction between Tx and Tg
[F(2,21)=.15, p=.87] was found.
Discussion
Although ICV-STZ has been used extensively to emulate metabolic changes found in the
AD brain, the findings of the current study provide inconsistent support for the use of an ICVSTZ model in mice with wild-type human tau. For many variables of interest for the Barnes
maze and western blotting, ICV-STZ did not result in an apparent induction or exacerbation of
pathology in the TauWT or TauP301L groups, respectively. It is unclear if the lack of ICV-STZ
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effect in the present study is due to an absence of pathology, perhaps due to a methodological
divergence from other ICV-STZ studies, or a lack of sensitive measures to detect subtle deficits.
Results of the Barnes maze did not indicate that there was a learning or memory deficit in
the Vehicle-TauP301L mice after approximately three months of tau expression. The total time
allowed for the expression of tau plays a key role in the presence and severity of pathology. It
may be possible that the assessed time-point was too early for the existence of detectable
learning and memory deficits. After two months of tau expression, TauP301L mice have been
shown to exhibit increases in long-term potentiation in the dentate gyrus and improvements in
spatial learning and memory accompanied by lower levels of tau phosphorylation than wildtypes at sites detected by AT8, AT180, and AD2 (Boekhoorn et al., 2006). This finding suggests
that it is not solely the presence of P301L tau that causes deficits in TauP301L mice; rather, the
time-dependent alterations in P301L tau such as tau cleavage (Rizzu et al., 2000),
hyperphosphorylation (Hoover et al., 2010; Ramsden et al., 2005; Terwel et al., 2005), and
mislocalization (Hoover et al., 2010; Kuchibhotla et al., 2014), that produce synaptic dysfunction
and cognitive decline. The mice in the present study represented a time-point at which early
pathology was expected, but it is possible that it was too premature and that deficits were not yet
present.
ICV-STZ also did not produce an obvious induction or exacerbation of behavioral
deficits. The period of time between surgery and subsequent behavioral testing and brain
analyses in the present study was long compared to other published reports. In most cases, the
time between STZ-treatment and biochemical and behavioral assays is fewer than six weeks
(Blokland & Jolles, 1993; Chen et al., 2013; de la Monte et al., 2006, Deng et al., 2009; Hoyer &
Lannert, 2008; Lester-Coll et al., 2006, Planel et al., 2007). The current study, in contrast,
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assessed behavioral deficits at three months post-surgery, and biochemical pathology 3.5 months
post-surgery. In one study of non-transgenic rats that received ICV-STZ, there were memory
deficits as measured by the MWM as far as two months post-surgery (Grünblatt et al., 2007). In
a study that encompassed the same time range between ICV-STZ and behavioral and
biochemical assays as the present study, it was noted that levels of active GSK3β, a kinase that
phosphorylates tau, in the hippocampus were significantly higher in ICV-STZ rats one month
post-surgery, but declined to control levels at three months post-surgery (Salkovic-Petrisic et al.,
2006). The same study, however, found memory deficits at both of the time-points as indicated
by the MWM (Salkovic-Petrisic et al., 2006). In one of the longest timeframes, nine-month-old
transgenic mice with a mutation in the Aβ precursor protein showed deficits in the MWM 6
months after ICV-STZ (Plaschke et al., 2010). Because the ICV-STZ studies with longer
timeframes used either non-transgenic rats or mice with Aβ mutations, it is unclear if there may
be partial or complete recovery of deficits from the effects of ICV-STZ in mice with human tau.
Future studies should investigate a potential resistance in human tau to long-term alterations
induced by ICV-STZ.
Although it is possible that there were no learning and memory deficits induced by ICVSTZ in the present study, one additional concern involves the possible inability of the Barnes
maze to have detected subtle deficits if present. The definition of search strategy, in particular,
may need to be revised to truly encompass a spatial search strategy. The definition of a serial
search strategy in the present study indicated that the first hole visited must be within two holes
of the target hole, and the mouse cannot visit a hole further than two holes from the target hole.
Because the Barnes maze used has 40 holes, this definition may be too restrictive. In a 12-hole
Barnes maze with mice, a serial search strategy was indicated by the mouse first visiting the
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target hole or the hole on either side, thus making 25% of the holes correspond to a serial search
strategy (Harrison et al., 2006). In a 20-hole Barnes maze, the same definition of a spatial search
strategy encompassing either adjacent hole was used, corresponding to a total of 15% of the
holes on the platform (Sunyer, Patil, Höger, & Lubec, 2007). In the 40-hole Barnes maze used in
the current study, only 12.5% of holes correspond to a spatial search strategy. This strict
definition may have resulted in coding some trials as serial or random even when a spatial search
strategy was being used. The persistent use of a serial search strategy is often an indication of a
spatial memory deficit (Harrison et al., 2006), and by coding a large number of trials as serial
due to strict requirements for a spatial search strategy, differences between truly impaired and
unimpaired mice are potentially minimized. Although amending the search strategy definitions
may improve the accuracy of future behavioral testing, in the present study, however, recoding
the search strategy for each trial was not warranted given the overall lack of significant main
effects.
An unexpected finding came from the significantly higher levels of CP-13
immunoreactivity in the TauWT mice compared to the TauP301L mice, regardless of STZ
exposure. The low levels of tau phosphorylation at Ser202 detected by CP-13, coupled with the
lack of consistent behavioral deficits, may again be explained by the facilitated learning and
memory reported in young TauP301L mice prior to the onset of severe pathology (Boekhoorn et
al., 2006).
Positive staining was not observed for PG-5 or Alz-50. Neither PG-5 nor Alz-50 have
been used in any studies evaluating the effects of STZ treatment. The epitope recognized by PG5, pSer409, is phosphorylated in a pKa-dependent manner (Jicha et al., 1999). Although it is
known that ICV-STZ acts through pathways involving GSK3β, PI3K-Akt (Ponce-Lopez, Liy-
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Salmeron, Hong, & Meneses, 2011), and Akt/GSK-3/PP-2A (Qu et al., 2011), it is unknown if a
pKa-dependent pathway capable of phosphorylating Ser409 is similarly induced by ICV-STZ.
Furthermore, lack of PG-5 immunoreactivity has previously been observed in TauP301L and
related mutations (Dutschmann et al., 2010; Vanhelmont et al., 2010) suggesting that the
particular mutation present in these models may not induce phosphorylation at Ser409. In
TauP301L and Tau-R406W (another FTDP-17 model of AD) mutations expressed in yeast,
levels of PG-5 epitopes are drastically reduced and almost absent, respectively, compared to
epitopes defined by other antibodies specific for pathological tau changes including AT8,
AT180, and AT270 (Vanhelmont et al., 2010). It is also possible that the timeframe of the
current study played a prominent role in the lack of PG-5 staining. PG-5 epitopes have been
characterized as absent or occasional until after four to 5.5 months of tau expression (Ramsden et
al., 2005). If the timeframe of the present study had continued beyond 3.5 months of tau
expression, it is possible that PG-5 epitopes could have been detected.
Even though the conformational change recognized by Alz-50 has been previously
detected after 2.5 months of tau expression in TauP301L mice (Ramsden et al., 2005) and even
after only three weeks in 3xTg-AD mice, which have a TauP301L mutation and mutations in Aβ
(Oh et al., 2010), no Alz-50 staining was found in the present study. Because there is no
literature on effects of ICV-STZ on Alz-50 immunoreactivity, it is unclear what effect STZ may
have on the amino acids involved in the conformation-specific change. In the present study, the
dilution of Alz-50 was 1:50, which has been shown to be strong enough to detect a prominent
signal (Ramsden et al., 2005; Uéda et al., 1990). However, dilutions as high as 1:10 have also
been successfully used (Vincent & Davies, 1990), and may have been capable of detecting a
weaker signal, if present at all.
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Even though there was no positive staining with PG-5 and Alz-50, there was detectable
immunoreactivity with PHF-1. It was not anticipated that late-stage markers of AD pathology
would be detected in the absence of the mid-stage markers; however, paired helical filaments
detected by PHF-1 have previously been found in high levels in STZ-treated rodents (Grünblatt
et al., 2007; Planel et al., 2007; Qu et al., 2011). At three months post ICV-STZ in three- to
four-month old male Wistar rats, levels of phosphorylated tau visualized through the use of PHF1 were significantly increased over vehicle-treated controls (Grünblatt et al., 2007). In nontransgenic mice injected peripherally with STZ, there was also a mild increase at 10 days postinfusion in the phosphorylation of Ser396 and Ser404, the sites recognized by PHF-1. This
significant increase continued to rise substantially through the final 40-day time-point (Planel et
al., 2007). The present study assessed pSer396 and pSer404 after approximately 3.5 months of
tau expression, and it is possible that the phosphorylation of PHF-1 epitopes similarly increased
with time.
It is still plausible that ICV-STZ treatment can be used to induce cerebral glucose
metabolism deficiencies in mice with human wild-type tau, but additional studies should use
alternative and multiple behavioral assays to detect subtle differences among groups. It may also
be necessary to train the mice for additional acquisition trials to improve the performance of the
Controls and thus increase the dynamic range. Future studies should also investigate effects of
ICV-STZ on human tau at different time periods post-surgery, and also at older ages at which
more severe pathology would be expected.
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Antibody

Species

Specificity

Use

Dilution

Tau-5

Mouse

Tau; human/mouse

Tau marker

1:1,000

Tau; conformational

Conformation specific; early

1:50

epitope, 7-9 and 326-

pathological change in AD

specific
MC-1

Mouse

330 aa
CP-13

Mouse

Tau; pSer202

Phosphorylation specific; early

1:50

pathological change in AD
PG-5

Mouse

Tau; pSer409

Pre-tangles; mid-stage

1:50

Alz-50

Mouse

Tau; conformational

Conformation specific; late-

1:50

epitope, 3-15 and 312-

stage

322 aa
PHF-1

Mouse

Tau; pSer396/pSer404

Paired helical filaments of tau;

1:50

late-stage
Actin

Goat

Anti-mouse

Sheep

Anti-goat

Donkey

C-terminus

Loading control

1:500

HRP-conjugated secondary

1:5,000

AP-conjugated secondary

1:5,000

Table 1. Antibodies used to assess tau pathology. Several antibodies capable of recognizing
distinct characteristics of tau pathology progression were used.
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Hole Deviation
F (1,50)=1.52,
Tx
p =.22
F (2,50)=0.74,
Tg
p =.48
F (2,50)=0.25,
Tx*Tg
p =.78
F (4,200)=2.02,
Day
p =.09
F (4,200)=1.52,
Day*Tx p =.20
F (8,200)=0.69,
Day*Tg p =.70
F (8,200)=0.54,
Day*Tx*Tg p =.83

Primary Errors
F (1,50)=0.22,
p =.64
F (2,50)=1.22,
p =.30
F (2,50)=0.58,
p =.56
F (4,200)=12.16,
p <.001***
F (4,200)=1.68,
p =.16
F (8,200)=2.771,
p< .01**
F (8,200)=1.01,
p =.43

Primary Latency
F (1,50)=1.13,
p =.29
F (2,50)=1.24,
p =.30
F (2,50)=1.50,
p =.23
F (4,200)=80.91,
p <.001***
F (4,200)=2.17,
p =.07
F (8,200)=0.16,
p =.99
F (8,200)=0.58
p =.79

Total Errors
F (1,50)=1.81,
p =.19
F (2,50)=1.80,
p =.18
F (2,50)=1.00,
p =.37
F (4,200)=8.34,
p <.001***
F (4,200)=1.49,
p =.21
F (8,200)=0.65,
p =.74
F (8,200)=1.98,
p =.05*
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Total Latency
F (1,50)=0.21,
p =.65
F (2,50)=3.88,
p =.03*
F (2,50)=0.39,
p =.68
F (4,200)=53.01,
p <.001***
F (4,200)=1.50,
p =.21
F (8,200)=0.50,
p =.86
F (8,200)=0.77,
p =.63

Table 2. Statistical results for acquisition. There were no significant effects of Tx, Tx*Tg, or
Day*Tx on any variable, and with the exception of total latency (*p≤.05), there were also no
main effects of Tg. For primary errors (***p<.001), primary latency (***p<.001), total errors
(***p<.001), and total latency (***p<.001), there was a significant effect of Day. For primary
errors, there was a significant interaction between Day and Tg (**p<.01). Lastly, for total errors,
there was a significant Day*Tx*Tg interaction (*p≤.05).
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Tg
Tx
TgTx

Random
X (3)=2.2,
p =.54
X (3)=7.0,
p =.07
X (15)=19.30,
p =.20

Day 1
Serial
X (3)=1.84,
p =.61
X (3)=9.05,
p =.03*
X (15)=25.84,
#

p =.04
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Spatial
X (2)=3.48,
p =.18
X (2)=1.02,
p =.60

Random
X (3)=2.39,
p =.50
X (3)=1.57,
p =.67

Day 2
Serial
X (3)=3.90,
p =.27
X (3)=1.11,
p =.77

X (10)=8.18,
p =.61

X (15)=14.84,
p =.46

X (15)=13.05,
p =.60

X (5)=4.77,
p =.45

Random
X (2)=3.18,
p =.20
X (2)=0.92,
p =.63
X (10)=6.57,
p =.77

Day 4
Serial
X (3)=3.24,
p =.36
X (3)=1.46,
p =.69
X (15)=9.54,
p =.85

Spatial
X (2)=1.28,
p =.53
X (2)=2.02,
p =.37
X (10)=9.33,
p =.50

Random
X (3)=2.05,
Tg
p =.56
X (3)=2.02,
Tx
p =.57
X (15)=16.35,
TxTg
p =.36

Day 3
Serial
X (3)=2.30,
p =.51
X (3)=1.24,
p =.74
X (15)=13.78,
p =.54

Spatial
X (2)=0.52,
p =.77
X (2)=1.13,
p =.57
X (10)=9.68,
p =.47

Random
X (2)=3.18,
Tg
p =.20
X (2)=1.13,
Tx
p =.57
X (10)=10.75,
TxTg
p =.38

Day 5
Serial
X (3)=4.35,
p =.28
X (3)=4.37,
p =.22
X (15)=24.42,
p =.06

Spatial
X (2)=1.28,
p =.53
X (2)=4.28,
p =.12
X (10)=15.42,
p =.12

Spatial
X (1)=0.83,
p =0.64
X (1)=0.33,
p =.57

Table 3. Search strategy. On Day 1, there was a significant effect of Tx for the use of a serial
search strategy in that a serial approach was utilized more often by mice in the vehicle-treated
group than the STZ-treated group (*p=.03). There was also a TxTg effect for serial search
strategy on Day 1 such that the Vehicle-TauWT mice the serial search strategy significantly
more often than the STZ-Control mice (#p=.04).
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Tx
Tg
Escape Latency
F (1,50)=0.20, p =.66 F (2,50)=0.51, p =.61
Escape Holes 0-30s F (1,50)=0.79, p =.38 F (2,50)=0.20, p =.82
Escape Holes 31-60s F (1,50)=0.38, p =.54 F (2,50)=0.05, p =.96
Escape Holes 61-90s F (1,50)=0.00, p =.98 F (2,50)=1.70, p =.19
Probe 1 Escape Holes Total F (1,50)=0.06, p =.81 F (2,50)=0.29, p =.75
Error Holes 0-30s
F (1,50)=4.39, p =.04* F (2,50)=0.33, p =.72
Error Holes 31-60s F (1,50)=3.89, p =.05* F (2,50)=2.69, p= .08
Error Holes 61-90s F (1,50)=7.09, p =.01* F (2,50)=2.06, p =.14
F (1,50)=5.49, p =.02* F (2,50)=2.90, p =.06
Error Holes Total
Escape Latency
Escape Holes 0-30s
Escape Holes 31-60s
Escape Holes 61-90s
Probe 2 Escape Holes Total
Error Holes 0-30s
Error Holes 31-60s
Error Holes 61-90s
Error Holes Total
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Tx*Tg
F (2,50)=1.38, p =.26
F (2,50)=1.12, p =.34
F (2,50)=0.44, p =.65
F (2,50)=1.79, p =.18
F (2,50)=1.25, p =.29
F (2,50)=3.34, p =.04*
F (2,50)=0.31, p =.73
F (2,50)=0.23, p =.79
F (2,50)=0.70, p =.50

F (1,50)=0.61, p =.44 F (2,50)=0.64, p =.89 F (2,50)=1.22, p =.30
F (1,50)=0.20, p =.66 F (2,50)=1.54, p =.23 F (2,50)=0.29, p =.75
F (1,50)=2.05, p =.16 F (2,50)=0.09, p =.91 F (2,50)=0.73, p =.49
F( 1,50)=0.24, p =.63 F (2,50)=1.06, p =.36 F (2,50)=0.48, p =.62
F (1,50)=0.61, p =.44 F =(2,50)=0.15, p =.86 F(2,50)=0.39, p =.68
F (1,50)=4.08, p =.05* F (2,50)=1.28, p =.51 F(2,50)=0.56, p =.57
F (1,50)=0.68, p =.42 F (2,50)=0.12, p =.89 F(2,50)=0.09, p =.92
F (1,50)=1.81, p =.19 F (2,50)=0.02, p =.98 F(2,50)=0.58, p =.57
F (1,50)=2.31, p =.13 F (2,50)=0.12, p =.88 F(2,50)=0.17, p =.85

Table 4. Statistical results for Probe 1 and Probe 2. Although there were no significant Tg
effects, for all bins of Probe 1 and the 0-30 s bin of Probe 2, there were significant effects of Tx
(*p≤.05). There was also a significant interaction between Tx and Tg in the 0-30 s bin of Probe
1 (*p≤.05).
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Figure 1. Mouse models and timeline. (A) There was a total of 56 male mice in the experiment,
with nine to eleven mice in each group. (B) Both TauWT and TauP301L responder lines encode
for human 4R tau lacking the amino terminal sequences (4R0N). The activator line used a
forebrain specific promoter (CaMKIIα) to restrict tau expression to AD relevant brain regions.
The addition of doxycycline (40 ppm) to the drinking water prevents the transcription of tau by
preferentially binding to the tetracycline transactivator protein. When doxycycline is removed,
transcription occurs. (C) Tau expression was suppressed during development using doxycycline
and turned on from two to five months of age. ICV-STZ or ICV-vehicle surgery was performed
at two months of age, and at the same time, tau expression began.
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Figure 2. Physiological parameters. (A) Body weight, (B) blood glucose levels, and (C) brain
weights did not differ among treatment or transgene groups.
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Figure 3. Hole deviation. Unlike the other acquisition variables, there was no significant trend
of improvement for hole deviation across days.
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Figure 4. Primary errors. (A) Fewer visits to error holes were made as the acquisition days
progressed. (B) On Day 1 of acquisition, there was a Day*Tg interaction in which the TauWT
mice made significantly more errors than the Control mice (TauWT vs. Control: *p=.04), but did
not differ on any other days (p>.05).
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Figure 5. Primary latency. The time required for the mice to initially locate the target hole
decreased with subsequent acquisition days.
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Figure 6. Total errors. The Vehicle-TauP301L mice made more errors than either the STZControl (Vehicle-TauP301L vs. STZ-Control: *p=.01) or Vehicle-TauWT (Vehicle-TauP301L
vs. STZ-Control: #p=.02) on Day 5.
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Figure 7. Total latency. (A) All of the groups made improvements in finding the escape box
across days. (B) For total latency, there was a Tg effect such that the TauP301L mice
consistently required more time to get into the escape box than the Control mice (*p=.03) but not
the TauWT mice (p=.16).
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Figure 8. Search strategy on day 1of acquisition. (A) The vehicle-treated mice were
significantly more likely to use a random search strategy and less likely to use a serial strategy
than the vehicle-treated mice (Vehicle vs. STZ: *p=.03). (B) There was also a Tx*Tg interaction
for the use of a serial search strategy (Vehicle-TauWT vs. STZ-Control: #p=.04), in which the
Vehicle-TauWT mice were more likely to use a serial search strategy than the STZ-Control
mice.
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Figure 9. Probe 1 error hole visits. (A) Although there was no Tx*Tg interaction in the total bin,
(B) there was a Tx*Tg interaction for the 0-30 s bin such that the STZ-TauP301L mice made the
most errors of all groups, but the Vehicle-TauP301L mice made fewest errors (Tx*Tg: *p<.05).
There was no Tx*Tg interaction for either (C) the 31-60 s or 61-90 s bin.
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Figure 10. Tx effect for Probe 1 error hole visits. There was a significant Tx effect in each of
the bins such that STZ-treated mice made more errors than vehicle-treated mice (*p≤.05): total
(p=.02), 0-30 s (p=.05), 31-60 s (p=.05), and 61-90 s (p=.01).
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Figure 11. Probe 1 escape latency. There were no significant differences between treatment or
transgene groups in the time taken for mice to initially locate the escape hole where the escape
box was formerly located in Probe 1.
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Figure 12. Probe 1 escape hole visits. There were no differences among Tx and Tg in the
number of visits to the escape holes during any of the bins of Probe 1.
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Figure 13. Probe 2 error hole visits. (A) There was not a significant interaction between Tx and
Tg for error hole visits in the (A) total, (B) 0-30 s, (C) 31-60 s, or (D) 61-90 s bins.
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Figure 14. Tx effect for Probe 2 error hole visits. For the 0-30 s bin, the STZ-treated mice
visited significantly more error holes (*p=.05). In the remaining time bins, there were no
differences between Tx groups.
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Figure 15. Probe 2 escape latency. There were no significant differences among treatment or
transgene groups in the time taken for mice to initially locate the escape hole where the escape
box was formerly located in Probe 2.
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Figure 16. Probe 2 escape hole visits. There were no significant differences among Tx or Tg
groups in the (A) total number of visits to the escape holes or during the (B) 0-30 s, (C) 31-60 s,
or (D) 61-90 s bins.
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Figure 17. Western blotting with Tau-5. (A) The TauWT and TauP301L both had dark bands of
total tau detected by Tau-5 and normalized with actin. (B) Levels of total tau are lower in the
Control mice; in fact, (C) a main effect of Tg indicates that the TauWT and TauP301L mice had
significantly higher total tau levels (*p<.05) than the Control mice, but did not differ from each
other.
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Figure 18. Western blotting with MC-1. (A) Bands of an early-stage conformational change
detected by MC-1 were less profound than the bands of Tau-5 (n=40). (B) TauP301L mice had
the highest level of MC-1—detected pathology normalized by actin, and (C) a main effect of Tg
demonstrates that the TauP301L mice had significantly higher levels than the Control mice
(*p<.05) but not the TauWT mice.
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Figure 19. Western blotting with CP-13. (A) Faint bands of phosphorylated serine at the 202nd
(pSer202) position, an early-stage change in AD, were detected by CP-13 (n=40). (B) The
TauWT mice had higher levels of CP-13—detected changes normalized with actin. (C) A main
effect of Tg shows that the TauWT mice had significantly more pSer202 than the Control and
TauP301L mice (*p<.01).
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Figure 20. Western blotting with PHF-1. (A) PHF-1 identified paired helical filaments (n=27).
(B) Levels of paired helical filaments normalized with actin were low in Control mice and higher
in the TauWT and TauP301L mice. (C) The main effect of Tg was significant, indicating that
the TauP301L mice had higher levels of paired helical filaments than the Control mice (*p<.05),
but not the TauWT mice.

